Sumitomo Dainippon Pharma to Invest in and Start Joint Research and Development with MELTIN

Sumitomo Dainippon Pharma Co., Ltd. (Head Office: Osaka, Japan; Representative Director, President and CEO: Hiroshi Nomura hereinafter called “Sumitomo Dainippon Pharma”) announced today its decision to invest JPY700 million in MELTIN MMI (Head Office: Shinjuku, Tokyo, Japan; CEO: Masahiro Kasuya hereinafter called “MELTIN”). At the same time, the two companies signed a joint research and development agreement.

MELTIN aims to enhance the functionality of cyborg technologies and the combination of cutting-edge bio-signal processing and robotics. This combination is with the aim of allowing humans to transcend their physical restriction and unleash their creativity for creating a world where they can live happily and freely.

With a focus on the three research areas of Psychiatry & Neurology, Oncology, and Regenerative Medicine / Cell Therapy, Sumitomo Dainippon Pharma is primarily involved in the pharmaceutical business and has identified healthcare areas other than pharmaceuticals as “Frontier Areas” with the aim of exploring new business opportunities.

Approving of MELTIN’s vision, Sumitomo Dainippon Pharma has decided to invest in MELTIN and, as part of its efforts to pioneer frontier areas, to conduct joint research and development of medical devices and others by utilizing MELTIN’s technology. Sumitomo Dainippon Pharma aims to deliver new value that benefits patients, leveraging its many years of knowledge in the pharmaceutical business.

<Reference information>
MELTIN corporate profile
Company name: MELTIN MMI
CEO: Masahiro KASUYA, Ph.D.
Founded: July 2013
URL: https://www.meltin.jp/en/

Contact:
Public & Investor Relations Group, Corporate Governance
Sumitomo Dainippon Pharma Co., Ltd.
TEL: +81-6-6203-1407 (Osaka); +81-3-5159-3300 (Tokyo)